270 related articles for article (PubMed ID: 9692719)
1. trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study.
Benisty S; Boissiere F; Faucheux B; Agid Y; Hirsch EC
Neuroscience; 1998 Oct; 86(3):813-26. PubMed ID: 9692719
[TBL] [Abstract][Full Text] [Related]
2. Expression of trkB and trkC mRNAs by adult midbrain dopamine neurons: a double-label in situ hybridization study.
Numan S; Seroogy KB
J Comp Neurol; 1999 Jan; 403(3):295-308. PubMed ID: 9886032
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain.
Yamada M; Yamada M; Richelson E
Neuroscience; 1995 Jan; 64(2):405-17. PubMed ID: 7700529
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs.
Seroogy KB; Lundgren KH; Tran TM; Guthrie KM; Isackson PJ; Gall CM
J Comp Neurol; 1994 Apr; 342(3):321-34. PubMed ID: 7912699
[TBL] [Abstract][Full Text] [Related]
5. Expression of catalytic trkB gene in the striatum and the basal forebrain of patients with Alzheimer's disease: an in situ hybridization study.
Boissière F; Faucheux B; Agid Y; Hirsch EC
Neurosci Lett; 1997 Jan; 221(2-3):141-4. PubMed ID: 9121684
[TBL] [Abstract][Full Text] [Related]
6. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.
Counihan TJ; Penney JB
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):164-9. PubMed ID: 9703165
[TBL] [Abstract][Full Text] [Related]
7. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
[TBL] [Abstract][Full Text] [Related]
8. Expression of neurotrophin and trk receptor genes in adult rats with fimbria transections: effect of intraventricular nerve growth factor and brain-derived neurotrophic factor administration.
Venero JL; Knüsel B; Beck KD; Hefti F
Neuroscience; 1994 Apr; 59(4):797-815. PubMed ID: 8058122
[TBL] [Abstract][Full Text] [Related]
9. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.
Uhl GR; Walther D; Mash D; Faucheux B; Javoy-Agid F
Ann Neurol; 1994 Apr; 35(4):494-8. PubMed ID: 8154880
[TBL] [Abstract][Full Text] [Related]
10. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study.
Javoy-Agid F; Hirsch EC; Dumas S; Duyckaerts C; Mallet J; Agid Y
Neuroscience; 1990; 38(1):245-53. PubMed ID: 1979431
[TBL] [Abstract][Full Text] [Related]
11. Temporal changes in the messenger RNA levels of cellular immediate early genes and neurotransmitter/receptor genes in the rat neostriatum and substantia nigra after acute treatment with eticlopride, a dopamine D2 receptor antagonist.
Sirinathsinghji DJ; Schuligoi R; Heavens RP; Dixon A; Iversen SD; Hill RG
Neuroscience; 1994 Sep; 62(2):407-23. PubMed ID: 7830888
[TBL] [Abstract][Full Text] [Related]
12. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
14. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression.
Yan Q; Matheson C; Sun J; Radeke MJ; Feinstein SC; Miller JA
Exp Neurol; 1994 May; 127(1):23-36. PubMed ID: 8200435
[TBL] [Abstract][Full Text] [Related]
15. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
Damier P; Hirsch EC; Agid Y; Graybiel AM
Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
[TBL] [Abstract][Full Text] [Related]
16. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra.
Parain K; Murer MG; Yan Q; Faucheux B; Agid Y; Hirsch E; Raisman-Vozari R
Neuroreport; 1999 Feb; 10(3):557-61. PubMed ID: 10208589
[TBL] [Abstract][Full Text] [Related]
18. Expression of ciliary neurotrophic factor receptor-alpha messenger RNA in neonatal and adult rat brain: an in situ hybridization study.
Lee MY; Hofmann HD; Kirsch M
Neuroscience; 1997 Mar; 77(1):233-46. PubMed ID: 9044389
[TBL] [Abstract][Full Text] [Related]
19. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
20. Microtopography of D1 dopaminergic binding sites in the human substantia nigra: an autoradiographic study.
Thibaut F; Hirsch EC; Raisman R; Javoy-Agid F; Agid Y
Neuroscience; 1990; 37(2):387-98. PubMed ID: 1983469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
